By Robert Simison and Elizabeth Lopatto
June 7 (Bloomberg) -- Biomet Inc., a maker of orthopedic implants, agreed to a sweetened $11.4 billion buyout offer from private equity firms after a lower bid was criticized by one of the biggest shareholders and an advisory firm.
The new $46-a-share proposal is 4.5 percent higher than the $44 that Blackstone Group LP, Kohlberg Kravis Roberts & Co., TPG, and the private-equity arm of Goldman Sachs Group Inc. had made. Biomet, based in Warsaw, Indiana, said in a statement today that it canceled a vote set for tomorrow on the old bid.
The buying group will start a tender offer by June 14, Biomet said. The increased bid may close a dispute over the company's value set off in December when Biomet accepted the equity group's $10.9 billion offer. Smith & Nephew Plc, Europe's biggest maker of orthopedic devices, said Biomet rejected its higher bid, and Institutional Shareholder Services recommended that investors vote against the transaction.
Thursday, June 7, 2007
Subscribe to:
Posts (Atom)